Immutrin: Funding, Investors & Team (Oct 2026)
Immutrin is a biotechnology company developing next‑generation antibody therapies designed to clear systemic amyloid deposits and reverse amyloidosis, this company lead asset targets ATTR cardiomyopathy, a severe and progressive form of amyloidosis, and its antibody represents a potential best‑in‑class treatment engineered to selectively and specifically remove established amyloid fibrils.
Immutrin has raised $87.1M across 1 funding round on record, the most recent a Series A of $87.1M announced in Mar 2026.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Immutrin Company Profile and Key Stats
Latest funding round on record: Mar 2026.
Immutrin Funding Rounds
Immutrin Founders and Leadership Team
Contact details for the Immutrin team: 1 has a LinkedIn profile.
Start 14-day free trial →Immutrin Funding Compared to Other Biotechnology Startups
Immutrin's latest round of $87.1M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Immutrin in Biotechnology and Cambridge
Companies Similar to Immutrin
R1 Therapeutics is a clinical‑stage biopharmaceutical company focused on discovering and developing new drug…
The perfect package for any general surgical trainee or resident. Progress from beginner to advanced surgical…
Argonaute RNA company research projects build on existing intellectual property.
An innovative C elegans company that serves the biotech, nutrition, and other industries and fields of study…
ViaNautis, previously known as SomaServe, was established in 2018 as a separate entity from UCL under the…
Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of…
Biodexa Pharmaceuticals is an international specialty pharmaceutical company focused on oncology and other…
Concert Bio helps businesses create optimal microbial communities.
RQ Bio is a biotechnology company that develops long-acting monoclonal antibodies against seasonal influenza…
N4 Pharma is a drug reformulation company focused on developing and out licensing new versions of existing…
Laverock Therapeutics is working on developing a system for suppressing genes, which can be used to create…
Oak hill bio is a clinical-stage rare disease therapeutics company developing life-changing medicines.
Immutrin Funding FAQs
What does Immutrin do?
Immutrin is a biotechnology company developing next‑generation antibody therapies designed to clear systemic amyloid deposits and reverse amyloidosis, this company lead asset targets ATTR cardiomyopathy, a severe and progressive form of amyloidosis, and its antibody represents a potential best‑in‑class treatment engineered to selectively and specifically remove established amyloid fibrils.
How much funding has Immutrin raised?
Immutrin has raised $87.1M across 1 round on record. The most recent is a Series A of $87.1M announced in Mar 2026.
When did Immutrin last raise funding?
Immutrin's most recent funding round on record is a Series A of $87.1M, announced in Mar 2026.
Who founded Immutrin?
FundedIQ lists Mihriban Tuna (Founder) at Immutrin.
Where is Immutrin headquartered?
Immutrin is based in Cambridge, Cambridgeshire, United Kingdom.
How many employees does Immutrin have?
Immutrin is in the 1-10 employee band.
How does Immutrin's funding compare to other Biotechnology startups?
Immutrin's latest round of $87.1M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Immutrin Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Immutrin is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.